Moonlight Therapeutics Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Moonlight Therapeutics Inc. - overview
Established
2017
Location
Atlanta, GA, US
Primary Industry
Biotechnology
About
Founded in 2017 and based in Georgia, US, Moonlight Therapeutics Inc. operates as a biotechnology company that develops treatments for food allergies. The company was co-founded by CEO Dr. Samir Patel, COO Dr.
Vladimir Zarnitsyn, and Dr. Harvinder Gill. In October 2025, Moonlight Therapeutics Inc. received an undisclosed amount of grant funding from new investor CDMRP.
The company is focused on developing treatments for people suffering from food allergies. Moonlight Therapeutics offers its platform, TASIS — Targeted Allergen-Specific Immunotherapy which involves the application of a dermal stamp that uses microneedles to desensitize patients from food allergies. The company will use the October 2025 funding to start clinical trials for MOON101 in peanut-allergic individuals and to expand its immunotherapy platform to treat other food allergies.
Current Investors
Central Piedmont Investment Group, SeedtoB Capital, CDMRP
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Pharmaceutical Research & Development
Website
www.moonlighttx.com/
Company Stage
Series A
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.